secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0001549084-22-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics Q2 revenue up 57% to $3.5M; net loss widens to $3.0M
-----------------------------------------------------------------

- Revenue $3.5M (+57% YoY); EksoHealth $3.2M, EksoWorks $0.2M; 17 EksoNR units booked.
- Net loss $3.0M ($0.23/share) vs $1.3M loss ($0.10) in Q2 2021; gross margin 47% vs 58%.
- Received FDA 510(k) clearance for EksoNR for Multiple Sclerosis indication.
- Cash $31.9M at June 30, 2022, down from $40.4M at Dec 31, 2021.
- Gain on warrant revaluation $1.0M; R&D expense up 30% YoY on next-gen products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000154908422000048/0001549084-22-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000154908422000048/ekso-20220728.htm
  HTML page:      https://secwatch.observer/filing/0001549084-22-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer